The remote patient monitoring (RPM) sector is undergoing its most significant transformation since the pandemic-era boom, driven by a convergence of reimbursement updates, artificial intelligence integration, and a deliberate move beyond chronic disease management into acute and post-surgical care. Industry analysts and clinical leaders say the next 18 months will determine whether RPM becomes a standard-of-care pillar or remains a niche tool for tech-adept health systems.

Reimbursement Expansion and New Payment Models

In a long-anticipated move, the U.S. Centers for Medicare & Medicaid Services (CMS) finalized its 2025 Physician Fee Schedule in November, introducing two new add-on codes for RPM services that include synchronous video check-ins combined with asynchronous device data review. The codes, G0320 and G0321, are designed to compensate clinicians for time spent interpreting trends across multiple vital signs—not just single readings—a shift that acknowledges the complexity of managing patients with comorbid conditions.

“For years, RPM billing rewarded data collection over clinical interpretation,” said Dr. Elena Marsh, a health policy researcher at the University of Michigan and former CMS adviser. “The new codes signal that CMS wants RPM to be a cognitive service, not a telemetry pipe. That’s a fundamental change in how vendors will design their platforms.”

Simultaneously, several state Medicaid programs, including California and New York, have begun piloting value-based RPM bundles for postpartum hypertension and pediatric asthma, paying a fixed monthly rate per patient rather than per-device. Early data from California’s pilot, released in January, showed a 23% reduction in 30-day readmissions among enrollees, though the sample size remains small.

AI-Driven Triage and Predictive Escalation

The most visible trend at this year’s HIMSS and CES health tracks is the integration of machine learning into RPM platforms. Rather than simple threshold alerts—e.g., blood pressure above 160/90—vendors are deploying models that synthesize historical trends, medication adherence patterns, and social determinants of health to generate a risk score and recommend a specific action: schedule a telehealth visit, dispatch a home nurse, or escalate to emergency care.

One notable deployment comes from Baltimore-based LifeBridge Health, which launched an AI-enabled RPM program for heart failure patients in December. The system uses a gradient-boosting algorithm trained on 14 months of local EHR data to predict decompensation events 48 hours before clinical onset. In a 90-day internal review, the program reduced heart failure readmissions by 31% compared with a matched control group using traditional threshold alerts.

“The key is not to replace the clinician but to reduce alert fatigue,” said Dr. Priya Natarajan, chief medical information officer at LifeBridge. “Our nurses now spend 40% less time reviewing normal data and more time on high-risk patients. The algorithm doesn’t make the call; it prioritizes the queue.”

However, experts caution that AI-driven RPM must be validated across diverse populations. A study published in theJournal of Medical Internet Researchin January found that models trained predominantly on White, urban populations performed significantly worse for rural Black and Hispanic patients, with a 12% drop in sensitivity. Regulators are taking note: the FDA’s draft guidance on AI-enabled SaMD, released in early 2025, explicitly recommends subgroup performance analysis for RPM devices.

Acute Care at Home: The New Frontier

Perhaps the most consequential shift is the expansion of RPM into hospital-at-home (HaH) programs. While HaH existed pre-COVID, the CMS Acute Hospital Care at Home waiver—extended through 2026—has accelerated adoption. As of February 2025, more than 340 hospitals in 37 states operate certified HaH programs, nearly all relying on RPM for continuous oxygen saturation, heart rate, and respiratory rate monitoring.

The difference from traditional RPM is the intensity. HaH devices typically stream data every 15 minutes, and protocols require a registered nurse to review trends at least every four hours. Vendors like Biofourmis and Current Health have pivoted their platforms to support this “high-acuity” use case, adding features such as predictive sepsis alerts and automated nurse callbacks.

“We’re seeing RPM move from ‘check in once a day’ to ‘you are in my ICU, just at home,’” said Michael Chen, CEO of a mid-sized RPM device manufacturer that requested anonymity due to ongoing FDA submissions. “That requires hardware with failover connectivity, battery life of at least 72 hours, and software that can handle 96 vital sign data points per patient per day without crashing.”

Early outcomes are promising. A multi-center study from the Mayo Clinic, published inNEJM Catalystin January, reported that HaH patients with RPM had a median length of stay 2.1 days shorter than comparable inpatients, with no significant difference in mortality or 30-day complications. The cost savings were estimated at $3,400 per admission.

Market Consolidation and Interoperability Hurdles

The RPM vendor landscape, once fragmented with hundreds of small device makers, is consolidating. In the past six months, three major acquisitions occurred: Philips acquired the RPM software firm Medable’s remote monitoring division; Teladoc Health purchased the wearable sensor startup VitalConnect for $480 million; and Best Buy Health expanded its partnership with the hospital-at-home platform Contessa.

Yet interoperability remains the industry’s Achilles’ heel. Despite the widespread adoption of HL7 FHIR standards, many RPM platforms still struggle to integrate with legacy EHRs, particularly for streaming continuous data. The Office of the National Coordinator for Health IT (ONC) issued a new certification rule in December requiring EHRs to support real-time ingestion of RPM data via FHIR subscriptions, but compliance deadlines extend to 2027.

“The biggest bottleneck is not the device or the algorithm—it’s the plumbing,” said Dr. Sarah Okafor, a telehealth researcher at Johns Hopkins. “If the RPM data lands in a PDF attachment instead of a structured vital signs table, the entire clinical workflow breaks down. We need to treat data integration as a patient safety issue, not an IT project.”

Expert Outlook: Regulatory Clarity and Home-Based Diagnostics

Looking ahead, industry observers expect three key developments by late 2025. First, the FDA is expected to issue a final rule on Software as a Medical Device (SaMD) for RPM, clarifying which AI features require pre-market review versus which are considered low-risk clinical decision support. Second, new continuous glucose monitors (CGMs) with over-the-counter availability—such as the Dexcom Stelo and Abbott Lingo—are being repurposed for RPM programs beyond diabetes, including post-bariatric surgery nutritional monitoring and pre-diabetic lifestyle interventions.

Third, and most speculatively, several academic medical centers are piloting “home diagnostic hubs” that combine RPM devices with at-home blood draw kits and urine analysis sticks, aiming to replace routine lab visits entirely. The University of Utah’s program, launched in January, uses a single kit that collects micro-samples and sends them to a central lab via courier, with results automatically integrated into the RPM dashboard.

“The future of RPM is not a wearable on the wrist; it’s a comprehensive home-based clinical workspace,” said Dr. Marsh. “We’re moving toward a model where the home becomes the default site for routine and even acute care, and the hospital becomes reserved for procedures and intensive interventions. That will require new payment models, new device categories, and a rethinking of the clinician’s daily workflow.”

For now, the industry faces a paradox: the technology is ready, the reimbursement is improving, and the clinical evidence is mounting—but adoption remains uneven, particularly in rural and safety-net settings. As Dr. Natarajan noted, “We have the tools. The question is whether our health system has the will to redesign care around the patient’s home, not the hospital’s convenience.”

The next 12 months will be telling. With CMS’s new codes taking effect in April 2025 and the HaH waiver set for renewal debates in Congress, the RPM sector is poised for either a leap forward or a period of stalled growth—depending on how well it addresses the interoperability and equity challenges that remain unresolved.